<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04807660</url>
  </required_header>
  <id_info>
    <org_study_id>ACT0315</org_study_id>
    <nct_id>NCT04807660</nct_id>
  </id_info>
  <brief_title>Bacteriological Evaluation of Children With Otorrhea</brief_title>
  <official_title>Bacteriological Evaluation of Spontaneous Otorrhea in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association Clinique Thérapeutique Infantile du val de Marne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association Clinique Thérapeutique Infantile du val de Marne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After pneumococcal conjugate vaccine implementation, the number of acute otitis media (AOM)&#xD;
      episodes has decreased, but AOM still remains among the most common diagnoses in childhood.&#xD;
      From 2% to 17% of cases of AOM feature spontaneous perforation of the tympanic membrane&#xD;
      (SPTM). The aim of this study was to describe the bacteriological causes of SPTM several&#xD;
      years after PCV13 implementation, in 2010.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Since October 2015, children with spontaneous perforation of the tympanic membrane (SPTM) are&#xD;
      prospectively enrolled by 41 pediatricians who are part of a research and teaching network&#xD;
      (ACTIV, Association Clinique et Thérapeutique Infantile du Val de Marne [Clinical and&#xD;
      Therapeutic Association of Val de Marne]) throughout France. For some patients, otorrhea is&#xD;
      the first manifestation of AOM; for others, otorrhea occurred after AOM treatment failure or&#xD;
      recurrence. Failure (non-responsive AOM) is defined as otorrhea appearing despite at least 48&#xD;
      hr of antibiotics or recurring less than 4 days after the end of antibiotic treatment.&#xD;
      Recurrence is defined by the appearance of otorrhea 4 to 30 days after the end of antibiotic&#xD;
      treatment for AOM.&#xD;
&#xD;
      Middle ear fluid (MEF) is obtained by sampling spontaneous discharge according to clinical&#xD;
      practice guidelines. MEF specimens are obtained with cotton-tipped wire swabs, immediately&#xD;
      placed in transport medium (Copan Venturi Transystem®, Brescia, Italy), and transported&#xD;
      within 48 hr to one of the two centralized microbiology laboratories (Robert Debré Hospital&#xD;
      or National Centre for Pneumococci at European Georges Pompidou Hospital, Paris, France).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2015</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Actual">October 1, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bacteria identification</measure>
    <time_frame>at inclusion</time_frame>
    <description>The percentage of children with otopathogens</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Describe the serotypes of S. pneumoniae</measure>
    <time_frame>at inclusion</time_frame>
    <description>percentage of each serotype</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the resistance of heamophilus influenzae</measure>
    <time_frame>at inclusion</time_frame>
    <description>percentage of resistant h. inlfuenzae</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Otorrhea</condition>
  <arm_group>
    <arm_group_label>Prospective cohort</arm_group_label>
    <description>Middle ear fluid sample for each enrrolled children</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>middle ear fluid sample</intervention_name>
    <description>middle ear fluid sample for each enrrolled children</description>
    <arm_group_label>Prospective cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        all children from 3 months to 15 years old with otorrhea&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  children from 3 months to 15 years old&#xD;
&#xD;
          -  with otorrhea&#xD;
&#xD;
          -  signed parents consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  children under 3 months&#xD;
&#xD;
          -  children &gt; 15 years old&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Corinne Levy, MD</last_name>
    <phone>0033148850404</phone>
    <email>corinne.levy@activ-france.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stéphane Béchet, MSc</last_name>
    <phone>0033148850404</phone>
    <email>sgtephane.bechet@activ-france.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ACTIV</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Levy, MD</last_name>
      <phone>0033148850404</phone>
      <email>corinne.levy@activ-france.fr</email>
    </contact>
    <contact_backup>
      <last_name>Stéphane Béchet, MSc</last_name>
      <phone>0033148850404</phone>
      <email>stephane.bechet@activ-france.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/30707730/</url>
    <description>Bacterial causes of otitis media with spontaneous perforation of the tympanic membrane in the era of 13 valent pneumococcal conjugate vaccine</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>otorrrhea</keyword>
  <keyword>children</keyword>
  <keyword>spontaneous perforation of the tympanic membrane</keyword>
  <keyword>ambulatory</keyword>
  <keyword>streptococcus pneumoniae</keyword>
  <keyword>heamophilus influenzae</keyword>
  <keyword>moraxella catarrhalis</keyword>
  <keyword>streptococcus pyogenes</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

